Intra-Cellular Therapies ITCI 深 滬
等待開盤 08-21 09:30:00 美东时间
131.87
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 131.87
- 總市值 1411.01万
- 52周最高 131.98
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 64.09
- 委 比 0.00%
- 總股本 0.00亿
- 歷史最高 131.98
- 量 比 0
- 振 幅 0.00%
- 歷史最低 6.75
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cybin reports Q1 results
Cybin press release (HELP): Q1 Net loss was $47.8 million for the quarter ended June 30, 2026, compared to a net loss of $24.6 million in the same period last year. Cash totaled $166.4 million as of J...
08-14 19:31
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Helus Pharma appointed Michael Halstead as CEO and reported progress in its clinical programs, including completion of enrollment in the Phase 3 APPROACH study for HLP003 in MDD, positive DDI results, and advancement of HLP004 for GAD. The company also completed a $50 million offering, strengthening its balance sheet. Financial highlights include $166.4 million in cash as of June 30, 2026, and a net loss of $47.8 million for the quarter.
08-14 11:28
解码致病通路 加快研发突破
（来源：中国医药报） 转自：中国医药报 近年来，与中枢神经系统（CNS）疾病相关的全球疾病负担持续上升，造成巨大的经济影响。预计到2030年，仅心理健康问题造...
08-06 07:59
Helus Pharma names ex-Intra-Cellular executive Michael Halstead as CEO
Helus Pharma (HELP) has appointed Michael Halstead as chief executive officer, effective immediately. Halstead previously served as president of Intra-Cellular Therapies, where he helped scale the com...
08-03 19:59
百亿美金并购新狂潮背后
原标题：百亿美金并购新狂潮背后 又一笔百亿美元级并购诞生。 7月6日，Vertex宣布以每股85美元、总价约100亿美元的全现金交易，正式将专注于内分泌罕见病...
07-08 10:19
